B-type natriuretic peptide and the diagnosis of acute heart failure

Reviews in Cardiovascular Medicine

Volumn 5, Issue SUPPL. 4, 2004, Pages

  Berkowitz, Robert ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B type natriuretic peptide; Heart failure; Nesiritide

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; INOTROPIC AGENT; LOOP DIURETIC AGENT; NESIRITIDE; NITROGEN; NITROPRUSSIDE SODIUM; OXYGEN; RENIN; UREA;

ACUTE HEART FAILURE; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIRCULATION; CLINICAL EXAMINATION; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; ELECTROCARDIOGRAPHY; EMERGENCY WARD; HEALTH ECONOMICS; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LABORATORY TEST; LUNG CAPILLARY PRESSURE; LUNG DISEASE; MEASUREMENT; PATIENT CARE; PHYSICAL EXAMINATION; PUBLIC HEALTH SERVICE; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; TREATMENT PLANNING;

DECISION TREES; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; EMERGENCY TREATMENT; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN;

EID: 12144260827     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. American Heart Association, American Stroke Association. Heart disease and stroke statistics - 2004 update. American Heart Association. Available at: http://www.americanheart.org/downloadable/heart /1072969766940HSStats2004Update.pdf. Accessed September 13, 2004.
2. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2001 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2004;1-198.
3. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States (2001-2003): rationale, design and preliminary observations from the Acute Decompensated Heart Failure National Registry (ADHERE™). Am Heart J. In press.
4. Peacock WF. Rapid optimization: strategies for optimal care of decompensated congestive heart-failure patients in the emergency department. Rev Cardiovasc Med. 2002;3(suppl 4):S41-S48.
5. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37:379-385.
6. Emerman CL. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency department. Rev Cardiovasc Med. 2003;4(suppl 7):S13-S20.
7. Shamsham F, Mitchell J. Essentials of the diagnosis of heart failure. Am Fam Physician. 2000;61:1319-1328.
8. Maisel AS, Krishnaswamy P, Nowak RM, et al, for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
9. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001; 38:2101-2113.
10. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin. 2001;19:557-571.
11. Peacock WF, Albert NM. Observation unit management of heart failure. Emerg Med Clin North Am. 2001;19:209-232.
12. Fonarow GC, Adams KF, Abraham WT, ADHERE Investigators. Risk stratification for in-hospital mortality in heart failure using classification and regression tree (CART) methodology: analysis of 33,046 patients in the ADHERE registry [abstract 290]. J Card Fail. 2003;9(suppl):S79.
13. Maisel A, Hollander JE, Guss D, et al, for the REDHOT Investigators. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328-1333.
14. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280-1287.
15. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94: 3184-3189.
16. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37-44.
17. Clemens LE, Almirez RG, Baudouin KA, et al. Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide. J Pharmacol Exp Ther. 1998;287:67-71.
18. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004;109:1680-1685.
19. Zellner C, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am J Physiol. 1999;276(3 pt 2):H1049-H1057.
20. Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation. 2003;107:2697-2701.
21. Aronson D, Burger AJ. Effect of nesiritide on endothelin-1 levels in patients with decompensated congestive heart failure [abstract 1046-71]. J Am Coll Cardiol. 2001; 37(2 suppl A):148A.
22. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37:1221-1227.
23. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000;97:4239-4244.
24. Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular disease. Congest Heart Fail. 2004;10(5 suppl 3):1-30.
25. Pfister R, Scholz M, Wielckens K, et al. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail. 2004;6: 289-293.
26. Ishii J, Nomura M, Ito M, et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta. 2000;301:19-30.
27. Haug C, Metzele A, Steffgen J, et al. Increased brain natriuretic peptide and atrial natriuretic peptide plasma concentrations in dialysis-dependent chronic renal failure and in patients with elevated left ventricular filling pressure. Clin Investig. 1994;72: 430-434.
28. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446.
29. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301-306.
30. O'Neill JO, Bott-Silverman CE, McRae AT III, et al. Can B-type natriuretic peptide levels be a surrogate marker for invasive hemodynamics during management of heart failure? [abstract 035]. J Card Fail. 2003;(9 suppl 1):S11.
31. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948-1955.
32. Maisel AS, McCord J, Nowak RM, et al, for the Breathing Not Properly Multinational Study Investigators. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol. 2003;41:2010-2017.
33. Angeja BG, Grossman W. Evaluation and management of diastolic heart failure. Circulation. 2003;107:659-663.
34. Matsumoto A, Hirata Y, Momomura S, et al. Effects of exercise on plasma level of brain natriuretic peptide in congestive heart failure with and without left ventricular dysfunction. Am Heart J. 1995;129: 139-145.
35. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-1021.
36. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriurefic peptide and prognosis in TAC-TICS-TIMI 18. J Am Coll Cardiol. 2003;41: 1264-1272.
37. Silverberg D, Wexler D, Blum M, et al. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens. 2004;13:163-170.
38. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41: 571-579.
39. Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc. 2001;76:1111-1119.
40. McCullough PA, Kuncheria J, Mathur VS. Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. Rev Cardiovasc Med. 2004;5:16-25.
41. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.
42. Krumholz HM, Chen Y-T, Wang Y, et al. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000;139:72-77.
43. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290: 2581-2587.
44. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002; 162:1689-1694.
45. Felker GM, Adams KF Jr, Konstam MA, et al. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J. 2003;145 (2 suppl):S18-S25.
46. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67.
47. Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9:13-25.
48. Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med. 2004;116:466-473.
49. Kellett J. Prediction of in-hospital mortality by brain natriuretic peptide levels and other independent variables in acutely ill patients with suspected heart disease. Can J Cardiol. 2004;20:686-690.
50. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002;39:131-138.
51. Berkowitz R, Ugwu OC, Dhruva V, Sedaghat D. Reduction in length of stay of heart failure admissions using B-type natriuretic peptide assay in the emergency department to facilitate early identification [abstract 394]. J Card Fail. 2003;(9 suppl 1): S105.
52. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386-391.
53. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001;7:21-29.
54. Richards AM, Doughty R, Nicholls MG, et al, for the Australia-New Zealand Heart Failure Group. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation. 1999; 99:786-792.
55. Morimoto T, Hayashino Y, Shimbo T, et al. Is B-type natriuretic peptide-guided heart failure management cost-effective? Int J Cardiol. 2004;96:177-181.
56. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
57. Peacock WF, Emerman CL, on behalf of the PROACTION Study Group. Safety and efficacy of nesiritide in the treatment of decompensated heart failure in observation patients [abstract 1027-89]. J Am Coll Cardiol. 2003;41(suppl A):336A.
58. Colucci WS, Elkayam U, Horton DP, et al, for the Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246-253.